#Lauruslab What went wrong
ARV formulations was 1500 cr business for Laurus, they didn't participate in tenders in Q1 at lower pricing thinking that would have impacted long term margins for entire 1500 crs. Q2 pricing went down further. Took them 2 qtrs to adjust to this..
ARV formulations was 1500 cr business for Laurus, they didn't participate in tenders in Q1 at lower pricing thinking that would have impacted long term margins for entire 1500 crs. Q2 pricing went down further. Took them 2 qtrs to adjust to this..
People say it couldn't deliver on promise. It has actually delivered fantasticaly on nonARV, CDMO.
ARV is where it went wrong and that was because of change in business dynamics similar to what happened in US generics few years back. Players are still not able to adjust to that
ARV is where it went wrong and that was because of change in business dynamics similar to what happened in US generics few years back. Players are still not able to adjust to that
On brighter side, it spent 1300 crs in last 18 months and will be spending similar in next 18 months. So effectively gross block will double from Mar'21 to Mar'24 and majority of that is towards nonARV and CDMO funded through internal accrual
In Mar'21, sales was 5000 crs with 15% from CDMO and 70% from ARV. You can have your guess for Mar'25 sales with % contribution from CDMO and Non-ARV.
2.5 Bn tablet European contracts will start in this qtr and next qtr. If alloted, Global funds ARV
2.5 Bn tablet European contracts will start in this qtr and next qtr. If alloted, Global funds ARV
supply will start from this qtr, it's 3 yrs contract. Large contract for animal health will start from Sep'23. 1 Mn lit fermentation capacity will start contributing from Mar'24.
CDMO and Non-ARV being scaled up superbly. It's long term investment thesis. I remain invested
CDMO and Non-ARV being scaled up superbly. It's long term investment thesis. I remain invested
• • •
Missing some Tweet in this thread? You can try to
force a refresh
